Multi-omics perspective: mechanisms of gastrointestinal injury repair

Abstract

In this review, we examine the significance of multi-omics technologies in understanding the plethora of intricate processes that activate gastrointestinal (GI) injury repair. Multi-omics, which includes genomics, transcriptomics, proteomics, and metabolomics, allows intricate mapping of cellular responses and molecular pathways involved in GI repair. We highlight the potential of multi-omics to discover previously unknown therapeutic targets or elucidate the molecular basis of the pathogenesis of GI. Furthermore, we explore the possibilities of integrating omics data to improve prediction models, and summarize the state-of-the-art technological developments and persisting obstacles that hinder the translation of multi-omics into clinical practice. Finally, innovative multi-omics approaches that can improve patient outcomes and advance therapeutic strategies in GI medicine are discussed.

Keywords

Gastroenterology / Multi-omics / Gastrointestinal repair / Inflammatory bowel disease

References

[1] Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Greer KB, Limketkai BN, et al. American College of Gastroenterology guidelines update: diagnosis and management of celiac disease. Am J Gastroenterol 2023; 118: 59-76. https://doi.org/10.14309/ajg.0000000000002075.

[2] Birk M, Bauerfeind P, Deprez PH, Häfner M, Hartmann D, Hassan C, et al. Removal of foreign bodies in the upper gastrointestinal tract in adults: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy 2016; 48: 489-96. https://doi.org/10.1055/s-0042-100456.

[3] Moayyedi P, Axon AT. Endoscopy and gastric ulcers. Endoscopy 1995; 27: 689-93. https://doi.org/10.1055/s-2007-1005789.

[4] Han Y, Liao Z, Li Y, Zhao X, Ma S, Bao D, et al. Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury. J Am Coll Cardiol 2022; 79: 116-28. https://doi.org/10.1016/j.jacc.2021.10.028.

[5] Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 2018; 154: 500-14. https://doi.org/10.1053/j.gastro.2017.10.049.

[6] Goldenring JR, Mills JC. Cellular plasticity, reprogramming, and regeneration: metaplasia in the stomach and beyond. Gastroenterology 2022; 162: 415-30. https://doi.org/10.1053/j.gastro.2021.10.036.

[7] Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol 2019; 17: 497-511. https://doi.org/10.1038/s41579-019-0213-6.

[8] Sun C, Wang A, Zhou Y, Chen P, Wang X, Huang J, et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat Commun 2023; 14: 2692. https://doi.org/10.1038/s41467-023-38360-5.

[9] Zheng W, Zhao S, Yin Y, Zhang H, Needham DM, Evans ED, et al. High-throughput, single-microbe genomics with strain resolution, applied to a human gut microbiome. Science 2022; 376: eabm1483. https://doi.org/10.1126/science.abm1483.

[10] Almeida A, Nayfach S, Boland M, Strozzi F, Beracochea M, Shi ZJ, et al. A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat Biotechnol 2021; 39: 105-14. https://doi.org/10.1038/s41587-020-0603-3.

[11] Islam, Khan MZ, Tam SY, Law HKW. Advances in high throughput proteomics profiling in establishing potential biomarkers for gastrointestinal cancer. Cells 2022; 11: 973-90. https://doi.org/10.3390/cells11060973.

[12] Huang CH, Chiou SH. Clinical proteomics identifies potential biomarkers in helicobacter pylori for gastrointestinal diseases. World J Gastroenterol 2014; 20: 1529-36. https://doi.org/10.3748/wjg.v20.i6.1529.

[13] Plevris N, Lees CW. Disease monitoring in inflammatory bowel disease: evolving principles and possibilities. Gastroenterology 2022; 162: 1456-1475.e1. https://doi.org/10.1053/j.gastro.2022.01.024.

[14] Uhlig HH, Muise AM. Clinical genomics in inflammatory bowel disease. Trends Genet 2017; 33: 629-41. https://doi.org/10.1016/j.tig.2017.06.008.

[15] Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 2015; 149: 1275-1285.e2. https://doi.org/10.1053/j.gastro.2015.07.003.

[16] Abyadeh M, Meyfour A, Gupta V, Zabet Moghaddam M, Fitzhenry MJ, Shahbazian S, et al. Recent advances of functional proteomics in gastrointestinal cancers-a path towards the identification of candidate diagnostic, prognostic, and therapeutic molecular biomarkers. Int J Mol Sci 2020; 21: 8532-57. https://doi.org/10.3390/ijms21228532.

[17] Roshani M, Molavizadeh D, Sadeghi S, Jafari A, Dashti F, Mirazimi SMA, et al. Emerging roles of miR-145 in gastrointestinal cancers: a new paradigm. Biomed Pharmacother 2023; 166: 115264. https://doi.org/10.1016/j.biopha.2023.115264.

[18] Shi W, Wang Y, Xu C, Li Y, Ge S, Bai B, et al. Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer. Nat Commun 2023; 14: 835. https://doi.org/10.1038/s41467-023-35797-6.

[19] Pelaseyed T, Bergström JH, Gustafsson JK, Ermund A, Birchenough GM, Schütte A, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev 2014; 260: 8-20. https://doi.org/10.1111/imr.12182.

[20] Ogulur I, Pat Y, Aydin T, Yazici D, Rückert B, Peng Y, et al. Gut epithelial barrier damage caused by dishwasher detergents and rinse aids. J Allergy Clin Immunol 2023; 151: 469-84. https://doi.org/10.1016/j.jaci.2022.10.020.

[21] Turner JR.Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799-809. https://doi.org/10.1038/nri2653.

[22] Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013; 70: 631-59. https://doi.org/10.1007/s00018-012-1070-x.

[23] Johansson ME, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 2013; 10: 352-61. https://doi.org/10.1038/nrgastro.2013.35.

[24] Dokoshi T, Chen Y, Cavagnero KJ, Rahman G, Hakim D, Brinton S, et al. Dermal injury drives a skin to gut axis that disrupts the intestinal microbiome and intestinal immune homeostasis in mice. Nat Commun 2024; 15: 3009. https://doi.org/10.1038/s41467-024-47072-3.

[25] Pan X, Zhu Q, Pan LL, Sun J. Macrophage immunometabolism in inflammatory bowel diseases: from pathogenesis to therapy. Pharmacol Ther 2022; 238: 108176. https://doi.org/10.1016/j.pharmthera.2022.108176.

[26] Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. Immunol Rev 2014; 260: 102-17. https://doi.org/10.1111/imr.12192.

[27] Gabanyi I, Muller PA, Feighery L, Oliveira TY, Costa-Pinto FA, Mucida D. Neuro-immune interactions drive tissue programming in intestinal macrophages. Cell 2016; 164: 378-91. https://doi.org/10.1016/j.cell.2015.12.023.

[28] Si X, Jia H, Liu N, Li J, Pan L, Wang J, et al. Alpha-Ketoglutarate attenuates colitis in mice by increasing lactobacillus abundance and regulating stem cell proliferation via Wnt-hippo Signaling. Mol Nutr Food Res 2022; 66: e2100955. https://doi.org/10.1002/mnfr.202100955.

[29] Yildiz S, Kinali M, Wei JJ, Milad M, Yin P, Adli M, et al. Adenomyosis: single-cell transcriptomic analysis reveals a paracrine mesenchymal-epithelial interaction involving the WNT/SFRP pathway. Fertil Steril 2023; 119: 869-82. https://doi.org/10.1016/j.fertnstert.2023.01.041.

[30] Lehmann M, Hu Q, Hu Y, Hafner K, Costa R, van den Berg A, et al. Chronic WNT/β-catenin signaling induces cellular senescence in lung epithelial cells. Cell Signal 2020; 70: 109588. https://doi.org/10.1016/j.cellsig.2020.109588.

[31] Katoh M.Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (review). Int J Oncol 2017; 51: 1357-69. https://doi.org/10.3892/ijo.2017.4129.

[32] Chen X, Tan H, Xu J, Tian Y, Yuan Q, Zuo Y, et al. Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/β-catenin signaling. Kidney Int 2022; 102: 506-20. https://doi.org/10.1016/j.kint.2022.04.028.

[33] Kwak SY, Shim S, Park S, Kim H, Lee SJ, Kim MJ, et al. Ghrelin reverts intestinal stem cell loss associated with radiation-induced enteropathy by activating notch signaling. Phytomedicine 2021; 81: 153424. https://doi.org/10.1016/j.phymed.2020.153424.

[34] Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol 2016; 8: a021873-a021897. https://doi.org/10.1101/cshperspect.a021873.

[35] Zhang T, Wang XF, Wang ZC, Lou D, Fang QQ, Hu YY, et al. Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. Biomed Pharmacother 2020; 129: 110287. https://doi.org/10.1016/j.biopha.2020.110287.

[36] Huang Z, Weng Y, Shen Q, Zhao Y, Jin Y. Microplastic: A potential threat to human and animal health by interfering with the intestinal barrier function and changing the intestinal microenvironment. Science of The Total Environment 2021; 785: 147365. https://doi.org/10.1016/j.scitotenv.2021.147365.

[37] Andreuzzi E, Capuano A, Poletto E, Pivetta E, Fejza A, Favero A, et al. Role of extracellular matrix in gastrointestinal cancer-associated angiogenesis. Int J Mol Sci 2020; 21: 3686-3719. https://doi.org/10.3390/ijms21103686.

[38] Kim S, Min S, Choi YS, Jo SH, Jung JH, Han K, et al. Tissue extracellular matrix hydrogels as alternatives to Matrigel for culturing gastrointestinal organoids. Nat Commun 2022; 13: 1692. https://doi.org/10.1038/s41467-022-29279-4.

[39] Rezakhani S, Gjorevski N, Lutolf MP. Extracellular matrix requirements for gastrointestinal organoid cultures. Biomaterials 2021; 276: 121020. https://doi.org/10.1016/j.biomaterials.2021.121020.

[40] Zhang Y, Li X, Luo Z, Ma L, Zhu S, Wang Z, et al. ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation. Proc Natl Acad Sci USA 2020; 117: 3083-92. https://doi.org/10.1073/pnas.1912774117.

[41] Merchant JL.Tales from the crypts: regulatory peptides and cytokines in gastrointestinal homeostasis and disease. J Clin Invest 2007; 117: 6-12. https://doi.org/10.1172/JCI30974.

[42] Kaymak T, Kaya B, Wuggenig P, Nuciforo S, Göldi A., Swiss EoE Cohort Study Group (SEECS), et al. IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis. Gut 2023; 72: 821-33. https://doi.org/10.1136/gutjnl-2022-327166.

[43] Chen Y, Mai Q, Chen Z, Lin T, Cai Y, Han J, et al. Dietary palmitoleic acid reprograms gut microbiota and improves biological therapy against colitis. Gut Microbes 2023; 15: 2211501. https://doi.org/10.1080/19490976.2023.2211501.

[44] Zhang J, Fan J, Zeng X, Nie M, Luan J, Wang Y, et al. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. Acta Pharm Sin B 2021; 11: 609-20. https://doi.org/10.1016/j.apsb.2020.10.022.

[45] Katoh M. Genomic testing, tumor microenvironment and targeted therapy of hedgehog-related human cancers. Clin Sci (Lond) 2019; 133: 953-70. https://doi.org/10.1042/CS20180845.

[46] Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater 2021; 6: 1973-87. https://doi.org/10.1016/j.bioactmat.2020.12.010.

[47] Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ. Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995; 108: 564-80. https://doi.org/10.1016/0016-5085(95)90087-X.

[48] Xian CJ. Roles of epidermal growth factor family in the regulation of postnatal somatic growth. Endocr Rev 2007; 28: 284-96. https://doi.org/10.1210/er.2006-0049.

[49] Dallas NA, Fan F, Gray MJ, van Buren G II, Lim SJ, Xia L, et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev 2007; 26: 433-41. https://doi.org/10.1007/s10555-007-9070-2.

[50] Xie K, Wei D, Shi Q, Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 2004; 15: 297-324. https://doi.org/10.1016/j.cytogfr.2004.04.003.

[51] Almeida A, Mitchell AL, Boland M, Forster SC, Gloor GB, Tarkowska A, et al. A new genomic blueprint of the human gut microbiota. Nature 2019; 568: 499-504. https://doi.org/10.1038/s41586-019-0965-1.

[52] Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65. https://doi.org/10.1038/nature08821.

[53] Do TH, Nguyen TT, Nguyen TN, Le QG, Nguyen C, Kimura K, et al. Mining biomass-degrading genes through Illumina-based de novo sequencing and metagenomic analysis of free-living bacteria in the gut of the lower termite Coptotermes gestroi harvested in Vietnam. J Biosci Bioeng 2014; 118: 665-71. https://doi.org/10.1016/j.jbiosc.2014.05.010.

[54] Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 2008; 24: 4-10. https://doi.org/10.1097/MOG.0b013e3282f2b0e8.

[55] Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019; 68: 1688-700. https://doi.org/10.1136/gutjnl-2018-317977.

[56] Kayama H, Okumura R, Takeda K. Interaction between the microbiota, epithelia, and immune cells in the intestine. Annu Rev Immunol 2020; 38: 23-48. https://doi.org/10.1146/annurev-immunol-070119-115104.

[57] Lai HC, Lin TL, Chen TW, Kuo YL, Chang CJ, Wu TR, et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide. Gut 2022; 71: 309-21. https://doi.org/10.1136/gutjnl-2020-322599.

[58] Nowicki-Osuch K, Zhuang L, Cheung TS, Black EL, Masqué-Soler N, Devonshire G, et al. Single-cell RNA sequencing unifies developmental programs of Esophageal and gastric intestinal metaplasia. Cancer Discov 2023; 13: 1346-63. https://doi.org/10.1158/2159-8290.CD-22-0824.

[59] Kang B, Camps J, Fan B, Jiang H, Ibrahim MM, Hu X, et al. Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment. Genome Biol 2022; 23: 265. https://doi.org/10.1186/s13059-022-02828-2.

[60] Duan ZQ, Li YX, Qiu Y, Shen Y, Wang Y, Zhang YY, et al. CD39 expression defines exhausted CD4(+) T cells associated with poor survival and immune evasion in human gastric cancer. Clin Transl Immunology 2024; 13: e1499. https://doi.org/10.1002/cti2.1499.

[61] Chen J, Liu K, Luo Y, Kang M, Wang J, Chen G, et al. Single-cell profiling of tumor immune microenvironment reveals immune irresponsiveness in gastric signet-ring cell carcinoma. Gastroenterology 2023; 165: 88-103. https://doi.org/10.1053/j.gastro.2023.03.008.

[62] Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang Z, et al. Intratumoral CXCL13(+)CD8(+)T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J Immunother Cancer 2021; 9: e001823. https://doi.org/10.1136/jitc-2020-001823.

[63] Chen J, Xu F, Ruan X, Sun J, Zhang Y, Zhang H, et al. Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses. EBioMedicine 2023; 89: 104494. https://doi.org/10.1016/j.ebiom.2023.104494.

[64] Chen J, Ruan X, Sun Y, Lu S, Hu S, Yuan S, et al. Multi-omic insight into the molecular networks of mitochondrial dysfunction in the pathogenesis of inflammatory bowel disease. EBioMedicine 2024; 99: 104934. https://doi.org/10.1016/j.ebiom.2023.104934.

[65] Levi-Galibov O, Lavon H, Wassermann-Dozorets R, Pevsner-Fischer M, Mayer S, Wershof E, et al. Heat shock factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer. Nat Commun 2020; 11: 6245. https://doi.org/10.1038/s41467-020-20054-x.

[66] Lin S, Wang J, Mukherjee PK, Mao R, West G, Czarnecki D, et al. Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis. Gut 2024; 73: 1110-23. https://doi.org/10.1136/gutjnl-2022-328608.

[67] Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol 2019; 4: 293-305. https://doi.org/10.1038/s41564-018-0306-4.

[68] Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol 2017; 2: 17004. https://doi.org/10.1038/nmicrobiol.2017.4.

[69] Li G, Lin J, Zhang C, Gao H, Lu H, Gao X, et al. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. Gut Microbes 2021; 13: 1968257. https://doi.org/10.1080/19490976.2021.1968257.

[70] Schirmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Gotman NM, et al. Compositional and temporal changes in the gut microbiome of Pediatric ulcerative colitis patients are linked to disease course. Cell Host Microbe 2018; 24: 600-610.e4. https://doi.org/10.1016/j.chom.2018.09.009.

[71] Hyams JS, Davis Thomas S, Gotman N, Haberman Y, Karns R, Schirmer M, et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet 2019; 393: 1708-20. https://doi.org/10.1016/S0140-6736(18)32592-3.

[72] Shaw KA, Bertha M, Hofmekler T, Chopra P, Vatanen T, Srivatsa A, et al. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Med 2016; 8: 75. https://doi.org/10.1186/s13073-016-0331-y.

[73] Ma J, Wang K, Wang J, Zeng Q, Liu K, Zheng S, et al. Microbial disruptions in inflammatory bowel disease: a comparative analysis. Int J Gen Med 2024; 17: 1355-67. https://doi.org/10.2147/IJGM.S448359.

[74] Meade S, Liu Chen Kiow J, Massaro C, Kaur G, Squirell E, Bressler B, et al. Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review. Gut Microbes 2023; 15: 2287073. https://doi.org/10.1080/19490976.2023.2287073.

[75] Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020; 17: 323-37. https://doi.org/10.1038/s41575-020-0273-0.

[76] Luiz-Ferreira A, Cola M, Barbastefano V, de-Faria F, Almeida A, Farias-Silva E, et al. Healing, antioxidant and cytoprotective properties of Indigofera truxillensis in different models of gastric ulcer in rats. Int J Mol Sci 2012; 13: 14973-91. https://doi.org/10.3390/ijms131114973.

[77] Alverdy JC, Hyoju SK, Weigerinck M, Gilbert JA. The gut microbiome and the mechanism of surgical infection. Br J Surg 2017; 104: e14-23. https://doi.org/10.1002/bjs.10405.

[78] Shan Y, Lee M, Chang EB. The gut microbiome and inflammatory bowel diseases. Annu Rev Med 2022; 73: 455-68. https://doi.org/10.1146/annurev-med-042320-021020.

[79] Qiu P, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The gut microbiota in inflammatory bowel disease. Front Cell Infect Microbiol 2022; 12: 733992. https://doi.org/10.3389/fcimb.2022.733992.

[80] Xiong Z, Li J, Huang R, Zhou H, Xu X, Zhang S, et al. The gut microbe-derived metabolite trimethylamine-N-oxide induces aortic valve fibrosis via PERK/ATF-4 and IRE-1α/XBP-1s signaling in vitro and in vivo. Atherosclerosis 2024; 391: 117431. https://doi.org/10.1016/j.atherosclerosis.2023.117431.

[81] Wypych TP, Pattaroni C, Perdijk O, Yap C, Trompette A, Anderson D, et al. Microbial metabolism of L-tyrosine protects against allergic airway inflammation. Nat Immunol 2021; 22: 279-86. https://doi.org/10.1038/s41590-020-00856-3.

[82] Chen S, Henderson A, Petriello MC, Romano KA, Gearing M, Miao J, et al. Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction. Cell Metab 2019; 30: 1141-1151.e5. https://doi.org/10.1016/j.cmet.2019.08.021.

[83] Navarro-Corcuera A, Sehrawat TS, Jalan-Sakrikar N, Gibbons HR, Pirius NE, Khanal S, et al. Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex. J Hepatol 2022; 76: 921-33. https://doi.org/10.1016/j.jhep.2021.12.014.

[84] Jalan-Sakrikar N, De Assuncao TM, Shi G, Aseem SO, Chi C, Shah VH, et al. Proteasomal degradation of enhancer of Zeste homologue 2 in Cholangiocytes promotes biliary fibrosis. Hepatology 2019; 70: 1674-89. https://doi.org/10.1002/hep.30706.

[85] Aseem SO, Jalan-Sakrikar N, Chi C, Navarro-Corcuera A, de Assuncao TM, Hamdan FH, et al. Epigenomic evaluation of Cholangiocyte transforming growth factor-β Signaling identifies a selective role for histone 3 lysine 9 acetylation in biliary fibrosis. Gastroenterology 2021; 160: 889-905.e10. https://doi.org/10.1053/j.gastro.2020.10.008.

[86] Yu FX, Meng Z, Plouffe SW, Guan KL. Hippo pathway regulation of gastrointestinal tissues. Annu Rev Physiol 2015; 77: 201-27. https://doi.org/10.1146/annurev-physiol-021014-071733.

[87] Xie Z, Wang Y, Yang G, Han J, Zhu L, Li L, et al. The role of the hippo pathway in the pathogenesis of inflammatory bowel disease. Cell Death Dis 2021; 12: 79. https://doi.org/10.1038/s41419-021-03395-3.

[88] An L, Cao Z, Nie P, Zhang H, Tong Z, Chen F, et al. Combinatorial targeting of hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers. J Clin Invest 2022; 132: e155468-e155486. https://doi.org/10.1172/JCI155468.

[89] Dey A, Varelas X, Guan KL. Targeting the hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov 2020; 19: 480-94. https://doi.org/10.1038/s41573-020-0070-z.

[90] Shen H, Huang X, Zhao Y, Wu D, Xue K, Yao J, et al. The hippo pathway links adipocyte plasticity to adipose tissue fibrosis. Nat Commun 2022; 13: 6030. https://doi.org/10.1038/s41467-022-33800-0.

[91] Guo L, Wang Y, Yang W, Wang C, Guo T’, Yang J, et al. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis. Gastroenterology 2023; 165: 414-428.e7. https://doi.org/10.1053/j.gastro.2023.04.029.

[92] Zhao Y, Feng Y, Liu M, Chen L, Meng Q, Tang X, et al. Single-cell RNA sequencing analysis reveals alginate oligosaccharides preventing chemotherapy-induced mucositis. Mucosal Immunol 2020; 13: 437-48. https://doi.org/10.1038/s41385-019-0248-z.

[93] Li L, Zhang Y, Ren Y, Cheng Z, Zhang Y, Wang X, et al. Pan-cancer single-cell analysis reveals the Core factors and pathway in specific cancer stem cells of upper gastrointestinal cancer. Front Bioeng Biotechnol 2022; 10: 849798. https://doi.org/10.3389/fbioe.2022.849798.

[94] Stidham RW, Takenaka K. Artificial intelligence for disease assessment in inflammatory bowel disease: how will it change our practice? Gastroenterology 2022; 162: 1493-506. https://doi.org/10.1053/j.gastro.2021.12.238.

[95] Da Rio L, Spadaccini M, Parigi TL, Gabbiadini R, Dal Buono A, Busacca A, et al. Artificial intelligence and inflammatory bowel disease: where are we going? World J Gastroenterol 2023; 29: 508-20. https://doi.org/10.3748/wjg.v29.i3.508.

[96] Ahmad HA, East JE, Panaccione R, Travis S, Canavan JB, Usiskin K, et al. Artificial intelligence in inflammatory bowel disease endoscopy: implications for clinical trials. J Crohns Colitis 2023; 17: 1342-53. https://doi.org/10.1093/ecco-jcc/jjad029.

[97] Chen G, Shen J. Artificial intelligence enhances studies on inflammatory bowel disease. Front Bioeng Biotechnol 2021; 9: 635764. https://doi.org/10.3389/fbioe.2021.635764.